Pharmacologic approaches to the treatment of chronic obstructive pulmonary disease (COPD) are evolving rapidly. Thinking outside of the current comfort zone will be required if treatment of COPD is to be improved, said respiratory experts during a symposium sponsored by Forest Laboratories at Chest 2010.
Nebulizer therapy for chronic obstructive pulmonary disease (COPD) receives high marks from patients and their caregivers, according to the results of 2 separate surveys presented at Chest 2010.
Inhalation therapy is a cornerstone of the treatment of COPD, because it is a targeted mode of delivery, produces high local concentrations of the active drug, and lessens systemic exposure. Several devices for inhalation therapy are available, including metered-dose inhalers, dry powder inhalers, and nebulizers.
Work productivity and quality of life are significantly worse in workers aged ≥65 years with chronic obstructive pulmonary disease (COPD) compared with those without COPD, according to survey data presented at Chest 2010.
Researchers examined the health outcomes of 3358 older employees (aged ≥65 years) using the US 2009 National Health and Wellness Survey, an online cross-sectional survey. Of these employees, 297 self-reported a diagnosis of COPD and 3061 did not.
Launched at Chest 2010, a new COPD Alliance is focusing on a national education campaign to raise the awareness of primary care physicians of chronic obstructive pulmonary disease (COPD) and bring about significant change in the diagnosis and treatment of this progressing, chronic disease.
In a comparison of 4 inhalers used in the treatment of chronic obstructive pulmonary disease (COPD), patients preferred the Genuair for its perceived ease of use. The Genuair also ranked highest in overall success rate, which was defined as patients’ ability to successfully open, prepare, close, and clean the inhaler.
Almost two thirds of patients and clinicians do not know the proper inhaler technique to get the maximal benefit of drug treatment for chronic obstructive pulmonary disease (COPD). A panel discussion focused on current and future aerosol drug delivery at Chest 2010.
Page 1 of 3
Results 1 - 10 of 22
Results 1 - 10 of 22